{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T21:28:04Z","timestamp":1776893284510,"version":"3.51.2"},"reference-count":49,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,10]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Patients who received R-chemo followed by MR had an improved 5-year PFS and OS independent of prognostic factors. A reduction of the risk of HT was observed among the MR patients of the training, but not of the validation, cohort.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018017673","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T15:55:32Z","timestamp":1530806132000},"page":"1562-1571","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study"],"prefix":"10.1182","volume":"2","author":[{"given":"C.","family":"Madsen","sequence":"first","affiliation":[{"name":"Department of Hematology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Clausen","sequence":"additional","affiliation":[{"name":"Department of Hematology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. L.","family":"Plesner","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pasanen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Helsinki University Hospital Comprehensive Cancer Centre, Helsinki, Finland;"},{"name":"Research Program Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kuismanen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Helsinki University Hospital Comprehensive Cancer Centre, Helsinki, Finland;"},{"name":"Research Program Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. H.","family":"Bentzen","sequence":"additional","affiliation":[{"name":"Department of Hematology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Department of Hematology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. B.","family":"Sillesen","sequence":"additional","affiliation":[{"name":"Department of Hematology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. M.","family":"Himmelstrup","sequence":"additional","affiliation":[{"name":"Department of Hematology, Roskilde Hospital, Roskilde, Denmark;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"R\u00f8nnov-Jessen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Vejle Hospital, Vejle, Denmark;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. R.","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aalborg University Hospital, Aalborg, Denmark;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Pettinger","sequence":"additional","affiliation":[{"name":"Health Sciences Research, Mayo Clinic, Rochester, MN; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ludvigsen","sequence":"additional","affiliation":[{"name":"Department of Hematology and"},{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lepp\u00e4","sequence":"additional","affiliation":[{"name":"Department of Oncology, Helsinki University Hospital Comprehensive Cancer Centre, Helsinki, Finland;"},{"name":"Research Program Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. A.","family":"d\u2019Amore","sequence":"additional","affiliation":[{"name":"Department of Hematology and"},{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2018,7,5]]},"reference":[{"issue":"19","key":"2019111617380251400_B1","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111617380251400_B2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the united states, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"20","key":"2019111617380251400_B3","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1182\/blood-2010-06-289561","article-title":"InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions","volume":"116","author":"Turner","year":"2010","journal-title":"Blood"},{"key":"2019111617380251400_B4","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"17","key":"2019111617380251400_B5","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2009.26.1693","article-title":"Prognostic factors in follicular lymphoma","volume":"28","author":"Relander","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111617380251400_B6","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111617380251400_B7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111617380251400_B8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":"Incidence, risk factors and outcome of histological transformation in follicular lymphoma","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111617380251400_B9","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111617380251400_B10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11912-012-0258-4","article-title":"Transformation in follicular lymphoma: biology, prognosis, and therapeutic options","volume":"14","author":"Wong","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"26","key":"2019111617380251400_B11","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111617380251400_B12","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111617380251400_B13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00277-013-1991-y","article-title":"Survival of patients with transformed lymphoma in the rituximab era","volume":"93","author":"Guirguis","year":"2014","journal-title":"Ann Hematol"},{"issue":"4","key":"2019111617380251400_B14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12570","article-title":"Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database","volume":"163","author":"Ban-Hoefen","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111617380251400_B15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group","volume":"178","author":"Alonso-\u00c1lvarez","year":"2017","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111617380251400_B16","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"28","key":"2019111617380251400_B17","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111617380251400_B18","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin\u2019s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9873","key":"2019111617380251400_B19","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"2019111617380251400_B20","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2019111617380251400_B21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.2015.61.3968","article-title":"Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35\/03","volume":"34","author":"Taverna","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9759","key":"2019111617380251400_B22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"17","key":"2019111617380251400_B23","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111617380251400_B24","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdw026","article-title":"Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era","volume":"27","author":"Cheah","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111617380251400_B25","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3109\/10428194.2015.1079313","article-title":"Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database","volume":"57","author":"Janikova","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2019111617380251400_B26","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/cncr.28659","article-title":"The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States","volume":"120","author":"Nastoupil","year":"2014","journal-title":"Cancer"},{"issue":"19","key":"2019111617380251400_B27","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/cncr.30137","article-title":"Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: a trial of the ECOG-ACRIN Cancer Research Group (E1496)","volume":"122","author":"Barta","year":"2016","journal-title":"Cancer"},{"issue":"27","key":"2019111617380251400_B28","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2012.44.8290","article-title":"Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi","volume":"31","author":"Vitolo","year":"2013","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111617380251400_B29","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111617380251400_B30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"issue":"suppl 15","key":"2019111617380251400_B31","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1200\/jco.2012.30.15_suppl.8049","article-title":"Transformation of follicular lymphoma in the era of immuno-chemotherapy: a population-based study from British Columbia [abstract]","volume":"30","author":"Al-Tourah","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl 7","key":"2019111617380251400_B32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1403494810393563","article-title":"The Danish pathology register","volume":"39","author":"Bjerregaard","year":"2011","journal-title":"Scand J Public Health"},{"key":"2019111617380251400_B33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CLEP.S9908","article-title":"Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank","volume":"2","author":"Erichsen","year":"2010","journal-title":"Clin Epidemiol"},{"issue":"6","key":"2019111617380251400_B34","doi-asserted-by":"crossref","first-page":"e0157999","DOI":"10.1371\/journal.pone.0157999","article-title":"The Danish National Lymphoma Registry: coverage and data quality","volume":"11","author":"Arboe","year":"2016","journal-title":"PLoS One"},{"key":"2019111617380251400_B35","doi-asserted-by":"crossref","unstructured":"Arboe B , JosefssonP. J\u00f8rgensenJ, et al. Danish National Lymphoma Registry. Clin Epidemiol. 2016;8:577-581.","DOI":"10.2147\/CLEP.S99470"},{"issue":"4","key":"2019111617380251400_B36","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group [published correction appears in J Clin Oncol. 2000;18(11):2351]","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111617380251400_B37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/biom.12451","article-title":"Instrumental variable method for time-to-event data using a pseudo-observation approach","volume":"72","author":"Kjaersgaard","year":"2016","journal-title":"Biometrics"},{"issue":"3","key":"2019111617380251400_B38","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/1536867X1001000308","article-title":"Regression analysis of censored data using pseudo-observations","volume":"10","author":"Parner","year":"2010","journal-title":"Stata J"},{"issue":"4","key":"2019111617380251400_B39","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10985-013-9290-4","article-title":"Events per variable for risk differences and relative risks using pseudo-observations","volume":"20","author":"Hansen","year":"2014","journal-title":"Lifetime Data Anal"},{"issue":"2","key":"2019111617380251400_B40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10985-013-9247-7","article-title":"Pseudo-observations for competing risks with covariate dependent censoring","volume":"20","author":"Binder","year":"2014","journal-title":"Lifetime Data Anal"},{"issue":"8","key":"2019111617380251400_B41","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/sim.4780120803","article-title":"Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?","volume":"12","author":"Pepe","year":"1993","journal-title":"Stat Med"},{"issue":"4","key":"2019111617380251400_B42","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1365-2141.1993.tb04697.x","article-title":"Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods","volume":"83","author":"Pepe","year":"1993","journal-title":"Br J Haematol"},{"key":"2019111617380251400_B43","first-page":"216","article-title":"Rituximab maintenance improves overall survival of patients with follicular lymphoma-individual patient data meta-analysis","volume-title":"Eur J Cancer","author":"Vidal","year":"2017"},{"issue":"3","key":"2019111617380251400_B44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clml.2012.12.011","article-title":"Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma","volume":"13","author":"Yared","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"2019111617380251400_B45","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.V128.22.1781.1781","article-title":"Rituximab maintenance after first line immunochemotherapy improves overall survival in patients with follicular lymphoma [abstract]","volume":"128","author":"Vilmar","year":"2016","journal-title":"Blood"},{"key":"2019111617380251400_B46","article-title":"Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma [published online ahead of print 23 May 2017]","author":"Bech","journal-title":"Br J Haematol"},{"issue":"19","key":"2019111617380251400_B47","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2019111617380251400_B48","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"2019111617380251400_B49","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study [published online ahead of print 27 March 2018]","author":"Cheson","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/13\/1562\/881309\/advances017673.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/13\/1562\/881309\/advances017673.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T04:56:19Z","timestamp":1604552179000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/13\/1562\/15926\/Upfront-rituximab-maintenance-improves-outcome-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,5]]},"references-count":49,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,7,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018017673","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,5]]}}}